Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1955 1
1965 1
1966 2
1967 4
1968 10
1969 5
1970 13
1971 17
1972 19
1973 24
1974 18
1975 17
1976 16
1977 4
1978 6
1979 15
1980 8
1981 14
1982 10
1983 13
1984 16
1985 18
1986 15
1987 9
1988 12
1989 16
1990 20
1991 25
1992 20
1993 22
1994 31
1995 22
1996 17
1997 16
1998 26
1999 23
2000 23
2001 22
2002 24
2003 25
2004 22
2005 24
2006 33
2007 41
2008 39
2009 32
2010 42
2011 63
2012 68
2013 75
2014 80
2015 87
2016 73
2017 75
2018 67
2019 110
2020 92
2021 132
2022 98
2023 85
2024 45

Text availability

Article attribute

Article type

Publication date

Search Results

1,814 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Intellectual disability-strabismus syndrome"
Page 1
PCDH19-Related Epilepsy Syndrome: A Comprehensive Clinical Review.
Samanta D. Samanta D. Pediatr Neurol. 2020 Apr;105:3-9. doi: 10.1016/j.pediatrneurol.2019.10.009. Epub 2019 Nov 30. Pediatr Neurol. 2020. PMID: 32057594 Review.
This disorder primarily manifests in heterozygote females due to random X chromosome inactivation leading to somatic mosaicism and abnormal cellular interference between cells with and without delta-protocadherin. This article reviews the clinical features based on …
This disorder primarily manifests in heterozygote females due to random X chromosome inactivation leading to somatic mosaicism and ab …
New Candidates for Autism/Intellectual Disability Identified by Whole-Exome Sequencing.
Bruno LP, Doddato G, Valentino F, Baldassarri M, Tita R, Fallerini C, Bruttini M, Lo Rizzo C, Mencarelli MA, Mari F, Pinto AM, Fava F, Fabbiani A, Lamacchia V, Carrer A, Caputo V, Granata S, Benetti E, Zguro K, Furini S, Renieri A, Ariani F. Bruno LP, et al. Int J Mol Sci. 2021 Dec 14;22(24):13439. doi: 10.3390/ijms222413439. Int J Mol Sci. 2021. PMID: 34948243 Free PMC article. Clinical Trial.
Intellectual disability (ID) is characterized by impairments in the cognitive processes and in the tasks of daily life. ...Here, we performed parent-offspring trio whole-exome sequencing (WES) in a cohort of 60 mostly syndromic ID/ASD patients and we detected 8 path …
Intellectual disability (ID) is characterized by impairments in the cognitive processes and in the tasks of daily life. ...Here, we p …
Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
Montouris G, Aboumatar S, Burdette D, Kothare S, Kuzniecky R, Rosenfeld W, Chung S. Montouris G, et al. Epilepsy Behav. 2020 Sep;110:107146. doi: 10.1016/j.yebeh.2020.107146. Epub 2020 Jun 18. Epilepsy Behav. 2020. PMID: 32563898 Free article. Review.
Lennox-Gastaut syndrome (LGS) is a severe developmental epileptic encephalopathy diagnosed in childhood that persists through adolescence and into adulthood. While the characteristics of LGS in pediatric patients are well defined, including "drop attacks", interictal slow …
Lennox-Gastaut syndrome (LGS) is a severe developmental epileptic encephalopathy diagnosed in childhood that persists through adolesc …
Topical corticosteroids for dry eye.
Liu SH, Saldanha IJ, Abraham AG, Rittiphairoj T, Hauswirth S, Gregory D, Ifantides C, Li T. Liu SH, et al. Cochrane Database Syst Rev. 2022 Oct 21;10(10):CD015070. doi: 10.1002/14651858.CD015070.pub2. Cochrane Database Syst Rev. 2022. PMID: 36269562 Free PMC article. Review.
Study characteristics and risk of bias All trials recruited adults aged 18 years or older, except one trial that enrolled children and adolescents aged between 3 and 14 years. Half of these trials involved predominantly female participants (median 79%, interquartile range …
Study characteristics and risk of bias All trials recruited adults aged 18 years or older, except one trial that enrolled children an …
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Devinsky O, et al. Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Epilepsia. 2014. PMID: 24854329 Free PMC article. Review.
CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic-ischemic encephalopathy. However, we lack data from well-powered double-blind randomized, controlled studies on the efficacy of pure …
CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic- …
A systematic review of cannabidiol trials in neurodevelopmental disorders.
Parrella NF, Hill AT, Enticott PG, Barhoun P, Bower IS, Ford TC. Parrella NF, et al. Pharmacol Biochem Behav. 2023 Sep;230:173607. doi: 10.1016/j.pbb.2023.173607. Epub 2023 Aug 4. Pharmacol Biochem Behav. 2023. PMID: 37543051 Free article. Review.
However, its suitability as a pharmaceutical intervention has not been reliably established in these clinical populations. This systematic review examines the nine published randomised controlled trials (RCTs) that have probed the safety and efficacy of CBD in indiv …
However, its suitability as a pharmaceutical intervention has not been reliably established in these clinical populations. This syste …
Non-speech oral motor treatment for children with developmental speech sound disorders.
Lee AS, Gibbon FE. Lee AS, et al. Cochrane Database Syst Rev. 2015 Mar 25;2015(3):CD009383. doi: 10.1002/14651858.CD009383.pub2. Cochrane Database Syst Rev. 2015. PMID: 25805060 Free PMC article. Review.
Individuals with an intellectual disability (e.g. Down syndrome) or a physical disability were not excluded. ...One study, a randomised controlled trial (RCT), included four boys aged seven years one month to nine years six months - all had speech soun …
Individuals with an intellectual disability (e.g. Down syndrome) or a physical disability were not excluded. ...One study, a …
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. PMID: 26599576 Free PMC article. Updated. Review.
At least 75% of participants needed to have an intellectual quotient of at least 70 (i.e. normal intellectual functioning). ...MAIN RESULTS: The studies.We included 38 parallel-group trials (5111 participants randomised) and 147 cross-over trials (7134 partic …
At least 75% of participants needed to have an intellectual quotient of at least 70 (i.e. normal intellectual functioning). .. …
Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials.
Sinha P, Kerchberger VE, Willmore A, Chambers J, Zhuo H, Abbott J, Jones C, Wickersham N, Wu N, Neyton L, Langelier CR, Mick E, He J, Jauregui A, Churpek MM, Gomez AD, Hendrickson CM, Kangelaris KN, Sarma A, Leligdowicz A, Delucchi KL, Liu KD, Russell JA, Matthay MA, Walley KR, Ware LB, Calfee CS. Sinha P, et al. Lancet Respir Med. 2023 Nov;11(11):965-974. doi: 10.1016/S2213-2600(23)00237-0. Epub 2023 Aug 23. Lancet Respir Med. 2023. PMID: 37633303
BACKGROUND: In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effective pharmacotherapies. ...We applied these models retrospectively to the previously published Prospective Recombinant Human Activated Protein …
BACKGROUND: In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effecti …
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT. Andre T, et al. Lancet Oncol. 2021 May;22(5):665-677. doi: 10.1016/S1470-2045(21)00064-4. Epub 2021 Apr 1. Lancet Oncol. 2021. PMID: 33812497 Clinical Trial.
To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses are reported here. METHODS: KEYNOTE-177 is an open-label, randomised, phase 3 trial being done at 192 cancer centres in 23 co …
To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses …
1,814 results